STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors

Spontaneous T cell responses against tumors occur frequently and have prognostic value in patients. The mechanism of innate immune sensing of immunogenic tumors leading to adaptive T cell responses remains undefined, although type I interferons (IFNs) are implicated in this process. We found that sp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Immunity (Cambridge, Mass.) Jg. 41; H. 5; S. 830
Hauptverfasser: Woo, Seng-Ryong, Fuertes, Mercedes B, Corrales, Leticia, Spranger, Stefani, Furdyna, Michael J, Leung, Michael Y K, Duggan, Ryan, Wang, Ying, Barber, Glen N, Fitzgerald, Katherine A, Alegre, Maria-Luisa, Gajewski, Thomas F
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 20.11.2014
Schlagworte:
ISSN:1097-4180, 1097-4180
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Spontaneous T cell responses against tumors occur frequently and have prognostic value in patients. The mechanism of innate immune sensing of immunogenic tumors leading to adaptive T cell responses remains undefined, although type I interferons (IFNs) are implicated in this process. We found that spontaneous CD8(+) T cell priming against tumors was defective in mice lacking stimulator of interferon genes complex (STING), but not other innate signaling pathways, suggesting involvement of a cytosolic DNA sensing pathway. In vitro, IFN-? production and dendritic cell activation were triggered by tumor-cell-derived DNA, via cyclic-GMP-AMP synthase (cGAS), STING, and interferon regulatory factor 3 (IRF3). In the tumor microenvironment in vivo, tumor cell DNA was detected within host antigen-presenting cells, which correlated with STING pathway activation and IFN-? production. Our results demonstrate that a major mechanism for innate immune sensing of cancer occurs via the host STING pathway, with major implications for cancer immunotherapy.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1097-4180
1097-4180
DOI:10.1016/j.immuni.2014.10.017